| 34.87 Delayed Data As of Aug 21 |  +0.26 / +0.75%Today’s Change | 33.97 Today|||52-Week Range 46.47 | -20.11% Year-to-Date |
| Teva Launches Generic Version of Mylan's EpiPen for KIds Aug 21 / Zacks.com - Paid Partner Content | Sarepta Stock Falls as FDA Denies Approval to Golodirsen Aug 20 / Zacks.com - Paid Partner Content |
| AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study Aug 21 / Zacks.com - Paid Partner Content | Deciphera Pharmaceuticals: Buy at the High? Aug 20 / MotleyFool.com - Paid Partner Content |
| Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco Aug 21 / Zacks.com - Paid Partner Content | Solid Biosciences Surges on DMD Gene Therapy Study Amendments Aug 19 / Zacks.com - Paid Partner Content |
| Bayer Sells Animal Health Division to Elanco: Now What? Aug 20 / Zacks.com - Paid Partner Content | Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY Aug 16 / Zacks.com - Paid Partner Content |
| Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales Aug 20 / Zacks.com - Paid Partner Content | Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth Aug 15 / Zacks.com - Paid Partner Content |
| Previous close | 34.61 |
| Today’s open | 34.94 |
| Day’s range | 34.82 - 35.12 |
| Volume | 18,226,251 |
| Average volume (3 months) | 25,331,983 |
| Market cap | $191.7B |
| Earnings growth (last year) | -46.78% |
| Earnings growth (this year) | -5.55% |
| Earnings growth (next 5 years) | +4.40% |
| Revenue growth (last year) | +2.10% |
| P/E ratio | 16.0 |
| Price/Sales | 4.86 |
| Price/Book | 3.13 |
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | +1.04 | +1.17% |
| MRKMerck | +1.26 | +1.47% |
| AZNAstraZeneca | +0.80 | +1.79% |
| LLYEli Lilly and Co | +0.45 | +0.41% |
| Next reporting date | October 29, 2019 |
| EPS forecast (this quarter) | $0.63 |
| Annual revenue (last year) | $53.6B |
| Annual profit (last year) | $11.2B |
| Net profit margin | 20.77% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Director, Chief Executive & Operating Officer Albert Bourla |
Chief Financial Officer & EVP-Business Operations Frank A. D'Amelio |
Corporate headquarters New York, New York |
